Today, the FDA authorized marketing of a test to detect human immunodeficiency virus (HIV) Type-1 drug resistance mutations using next generation sequencing (NGS) technology. It is the first HIV drug resistance assay that uses NGS that the FDA has authorized for marketing in the U.S.
Read more: FDA authorizes marketing of first next-generation sequencing test for detecting HIV-1 drug resistance mutations